Abstract
TNM staging remains the most widely applied and clinically useful prognostic marker for colorectal cancer. However, on-going clinical investigations of genes involved in carcinogenesis, profiling of metabolic pathways to determine a tumor's response to chemotherapy, and the evolution of new technology for the simultaneous evaluation of thousands of potential genetic markers promise to improve our ability as surgeons to provide accurate prognoses for individual patients. We review well-known prognostic and predictive genetic markers in colorectal cancer, with emphasis on the use of genomics for determining patient outcome following surgical resection.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
